CTXR announced that the FDA has issued a Complete Response Letter (CRL) regarding the Company's Biologics License Application (BLA) seeking approval for denileukin diftitox (LYMPHIR)#细胞因子#
| 发布于: | Android | 转发：0 | 回复：0 | 喜欢：0 |
CTXR announced that the FDA has issued a Complete Response Letter (CRL) regarding the Company's Biologics License Application (BLA) seeking approval for denileukin diftitox (LYMPHIR)#细胞因子#